Nasdaq · Biotech stocks database

EPRX — Eupraxia Pharmaceuticals Inc.

EPRX (Eupraxia Pharmaceuticals Inc.) stock: $6.89, $454.1M market cap, $12.8M cash, $441.3M EV, $496.4M fully diluted market cap. Next expected readout: Dec-26. Lead program: EP-104GI (Eosinophilic Esophagitis), Phase 2. Data from Fully Diluted's biotech stocks database.

What they do

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals, with lead candidate EP-104GI in clinical development for eosinophilic esophagitis.

Source: company website via company website

Share price

$6.89

Market cap

$454.1M

Cash

$12.8M

Enterprise value

$441.3M

Balance sheet

Cash	$12.8M
Debt	$0.0M
Net cash	$12.8M
Enterprise value	$441.3M
Basic shares	65.9M shares
Fully diluted shares	72.0M shares
Fully diluted market cap	$496.4M
Cash per share	$0.19
Quarterly burn	$7.1M
Cash runway	1.8 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

65.5M

Pre-funded warrants

1.4M

Options

3.0M

RSUs

0.0M

Warrants

1.5M

Converts

0.0M

Conv preferred

0.6M

ESPP reserve

0.0M

FDSO

72.0M

Cap table components pending verification.

Price history

Loading EPRX daily closes…

Loading price history…

Next catalyst

EP-104GI · Est. Nov 15, 2026 · quarter midpoint · guided Now

Recently reported

EP-104GI Phase 1 Mixed · 2026-09-30

EP-104GI · eosinophilic esophagitis

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	EP-104GI RESOLVE Phase 2b in eosinophilic esophagitis (interim)	Phase 2b	eosinophilic esophagitis ()	Q4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	EP-104GI
Lead indication	Eosinophilic Esophagitis
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05608681	Phase 2	Recruiting	Sponsor	EPRX	—	Eosinophilic Esophagitis	Q4 2026 Est. Nov 15, 2026 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Eupraxia Pharmaceuticals Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Vivo Capital	1,350,000	no change	0.81%	2026-08-14
Great Point Partners	1,200,000	no change	1.87%	2026-08-14
Ikarian Capital	809,741	-405,000	0.88%	2026-08-14
Aisling Capital	325,000	no change	0.46%	2026-08-13
OrbiMed Advisors	269,000	+269,000	0.03%	2026-08-14
Ally Bridge Group	252,175	-408,200	2.15%	2026-08-14
DAFNA Capital	225,600	+225,600	0.28%	2026-08-14
Stonepine Capital	43,491	+43,491	0.22%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

EPRX — Eupraxia Pharmaceuticals Inc.

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

EPRX — Eupraxia Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

EPRX — Eupraxia Pharmaceuticals Inc.